Back to News
Market Impact: 0.2
Aclaris Therapeutics, Inc. Announces Phase 1b Results for ATI-052 and Estimates $204.6 million in Cash
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Aclaris Therapeutics announced primary analysis results from Phase 1b proof-of-concept trials of ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, in severe atopic dermatitis and mild-to-moderate asthma. The provided article text ends before reporting the results, so efficacy, safety, and any market implications cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- SK Hynix Posts Record Profit Amid AI Rush
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI
- Analysis-Hold or sell? High Treasury yields spur US banks to rethink bond portfolios
- Labubu-maker Pop Mart's shares extend declines as third-quarter sales plunge